Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $225
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $201 to $225.
Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $201 to $225.